Icon (ICLR) – Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Icon (NASDAQ: ICLR):

• 10/29/2026 – Icon had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $235.00 price target on the stock.
• 10/29/2026 – Icon had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $250.00 price target on the stock.
• 10/29/2026 – Icon had its price target raised by Royal Bank Of Canada from $185.00 to $226.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – Icon had its price target raised by UBS Group from $195.00 to $236.00. They now have a “neutral” rating on the stock.
• 10/29/2026 – Icon had its price target raised by Citigroup from $175.00 to $215.00. They now have a “neutral” rating on the stock.
• 10/29/2026 – Icon had its price target raised by Barclays from $175.00 to $230.00. They now have an “equal weight” rating on the stock.
• 10/29/2026 – Icon had its price target raised by Truist Financial from $209.00 to $268.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Icon had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $254.00 price target on the stock.
• 10/29/2026 – Icon had its price target raised by TD Cowen from $197.00 to $254.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Icon had its price target raised by Robert W. Baird from $210.00 to $249.00. They now have an “outperform” rating on the stock.
• 10/28/2026 – Icon was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 10/28/2026 – Icon had its “outperform” rating reaffirmed by Evercore. They now have a $240.00 price target on the stock.
• 10/9/2026 – Icon was upgraded by Bank of America from “underperform” to “neutral”. They now have a $185.00 price target on the stock.
• 9/30/2026 – Icon is now covered by UBS Group. They set a “neutral” rating and a $195.00 price target on the stock.
• 9/30/2026 – Icon was upgraded by UBS Group to “hold”.
• 9/18/2026 – Icon had its price target lowered by Citigroup from $180.00 to $175.00. They now have a “neutral” rating on the stock.
• 9/17/2026 – Icon was upgraded by Citigroup to “hold”.

Insider Activity at Icon

In other Icon news, Director Ronan Murphy sold 5,005 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $175.00, for a total value of $875,875.00. Following the completion of the transaction, the director owned 3,847 shares in the company, valued at $673,225. This trade represents a 56.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Bernard Clerkin sold 2,267 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $372,445.43. Following the sale, the chief financial officer owned 5,881 shares in the company, valued at approximately $966,189.49. This trade represents a 27.82% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 23,068 shares of company stock worth $3,936,744 in the last three months. Corporate insiders own 44.00% of the company’s stock.

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.